Transdermal estradiol gel - BHR Pharma

Drug Profile

Transdermal estradiol gel - BHR Pharma

Alternative Names: BHR-200

Latest Information Update: 17 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BHR Pharma
  • Class Antineoplastics; Estradiol congeners; Estrenes; Hormonal replacements; Small molecules
  • Mechanism of Action Estrogen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Prostate cancer

Most Recent Events

  • 01 Mar 2017 BHR Pharma terminates a phase II trial in Prostate cancer in USA (NCT02349386) due to inability to recruit patients
  • 01 Jul 2015 Phase-II clinical trials in Prostate cancer in USA (Topical) (NCT02349386)
  • 02 Feb 2015 BHR Pharma plans a phase II trial for Prostate cancer (Late-stage disease) in USA (NCT02349386)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top